186 related articles for article (PubMed ID: 19176397)
1. The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone.
Trédan O; Garbens AB; Lalani AS; Tannock IF
Cancer Res; 2009 Feb; 69(3):940-7. PubMed ID: 19176397
[TBL] [Abstract][Full Text] [Related]
2. Selective tumor targeting by the hypoxia-activated prodrug AQ4N blocks tumor growth and metastasis in preclinical models of pancreatic cancer.
Lalani AS; Alters SE; Wong A; Albertella MR; Cleland JL; Henner WD
Clin Cancer Res; 2007 Apr; 13(7):2216-25. PubMed ID: 17404106
[TBL] [Abstract][Full Text] [Related]
3. Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix-assisted laser desorption/ionisation mass spectrometry.
Atkinson SJ; Loadman PM; Sutton C; Patterson LH; Clench MR
Rapid Commun Mass Spectrom; 2007; 21(7):1271-6. PubMed ID: 17340571
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study.
Albertella MR; Loadman PM; Jones PH; Phillips RM; Rampling R; Burnet N; Alcock C; Anthoney A; Vjaters E; Dunk CR; Harris PA; Wong A; Lalani AS; Twelves CJ
Clin Cancer Res; 2008 Feb; 14(4):1096-104. PubMed ID: 18281542
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced malignancies.
Papadopoulos KP; Goel S; Beeram M; Wong A; Desai K; Haigentz M; Milián ML; Mani S; Tolcher A; Lalani AS; Sarantopoulos J
Clin Cancer Res; 2008 Nov; 14(21):7110-5. PubMed ID: 18981010
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the antiangiogenic potential of AQ4N.
O'Rourke M; Ward C; Worthington J; McKenna J; Valentine A; Robson T; Hirst DG; McKeown SR
Clin Cancer Res; 2008 Mar; 14(5):1502-9. PubMed ID: 18316575
[TBL] [Abstract][Full Text] [Related]
7. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation.
Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S
Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269
[TBL] [Abstract][Full Text] [Related]
8. Tumor-selective drug activation: a GDEPT approach utilizing cytochrome P450 1A1 and AQ4N.
Yakkundi A; McErlane V; Murray M; McCarthy HO; Ward C; Hughes CM; Patterson LH; Hirst DG; McKeown SR; Robson T
Cancer Gene Ther; 2006 Jun; 13(6):598-605. PubMed ID: 16410820
[TBL] [Abstract][Full Text] [Related]
9. In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.
Williams KJ; Albertella MR; Fitzpatrick B; Loadman PM; Shnyder SD; Chinje EC; Telfer BA; Dunk CR; Harris PA; Stratford IJ
Mol Cancer Ther; 2009 Dec; 8(12):3266-75. PubMed ID: 19996276
[TBL] [Abstract][Full Text] [Related]
10. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
11. A preclinical pharmacokinetic study of the bioreductive drug AQ4N.
Loadman PM; Swaine DJ; Bibby MC; Welham KJ; Patterson LH
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):422-6. PubMed ID: 11259326
[TBL] [Abstract][Full Text] [Related]
12. A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N.
McErlane V; Yakkundi A; McCarthy HO; Hughes CM; Patterson LH; Hirst DG; Robson T; McKeown SR
J Gene Med; 2005 Jul; 7(7):851-9. PubMed ID: 15712360
[TBL] [Abstract][Full Text] [Related]
13. [Can tumor hypoxia be turned into a chemotherapeutic advantage?].
Trédan O; Grantab R; Dumontet C
Bull Cancer; 2008 May; 95(5):528-34. PubMed ID: 18541517
[TBL] [Abstract][Full Text] [Related]
14. DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS; Guise CP; Ferry DM; Pullen SM; Dorie MJ; Brown JM; Patterson AV; Wilson WR
Cancer Res; 2009 May; 69(9):3884-91. PubMed ID: 19366798
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
[TBL] [Abstract][Full Text] [Related]
16. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Saggar JK; Tannock IF
Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
[TBL] [Abstract][Full Text] [Related]
17. Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
Patel KJ; Trédan O; Tannock IF
Cancer Chemother Pharmacol; 2013 Jul; 72(1):127-38. PubMed ID: 23680920
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric analysis and confocal imaging of anticancer alkylaminoanthraquinones and their N-oxides in intact human cells using 647-nm krypton laser excitation.
Smith PJ; Desnoyers R; Blunt N; Giles Y; Patterson LH; Watson JV
Cytometry; 1997 Jan; 27(1):43-53. PubMed ID: 9000584
[TBL] [Abstract][Full Text] [Related]
19. DNA damage following combination of radiation with the bioreductive drug AQ4N: possible selective toxicity to oxic and hypoxic tumour cells.
Hejmadi MV; McKeown SR; Friery OP; McIntyre IA; Patterson LH; Hirst DG
Br J Cancer; 1996 Feb; 73(4):499-505. PubMed ID: 8595165
[TBL] [Abstract][Full Text] [Related]
20. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors.
Primeau AJ; Rendon A; Hedley D; Lilge L; Tannock IF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8782-8. PubMed ID: 16361566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
